Company Overview and News

West Kirkland Reports Multiple New High-Grade Gold Sections On Surface At Gold Mountain Target Hasbrouck Project, Tonopah, Nevada

2018-07-26 globenewswire
VANCOUVER, British Columbia, July 26, 2018 (GLOBE NEWSWIRE) -- West Kirkland Mining Inc. (TSXV:WKM) (“West Kirkland” or “Company”) reports the results of a further 345 composite surface samples from Gold Mountain, each taken across an interval of 20 feet and focused on areas of high interest identified by the extensive surface sampling completed by the Company in May, and reported in June 2018.

How Much Is Equinox Gold's Copper Arm Worth?

2018-06-28 seekingalpha
Warintza and La Verde hold 3.7 billion pounds of copper in the measured and indicated category and another 4.6 billion pounds of copper in the inferred category.

West Kirkland Reports 43m of 3.40 grams per tonne at surface Near Hasbrouck Project, Tonopah, Nevada

2018-05-22 globenewswire
VANCOUVER, British Columbia, May 22, 2018 (GLOBE NEWSWIRE) -- West Kirkland Mining Inc. (TSXV:WKM) (“West Kirkland”, “WKM” or the “Company”) is pleased to report further good gold assay results from the Gold Mountain target near the Company’s Hasbrouck Gold Project Reserves in Nevada.

Chinese Immigration Act, 1923 - Wikipedia

The Chinese Immigration Act, 1923, known today as the Chinese Exclusion Act,[1] was an act passed by the Parliament of Canada, banning most forms of Chinese immigration to Canada. Immigration from most countries was controlled or restricted in some way, but only the Chinese were so completely prohibited from immigrating.

West Kirkland Exploration Program Underway at Hasbrouck Project, Tonopah, Nevada

2018-04-16 globenewswire - 1
VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- West Kirkland Mining Inc. (TSXV:WKM) (“West Kirkland”, “WKM” or the “Company”) is pleased to report that a large program of surface geological mapping and continuous channel and chip sampling for gold is underway on the 100% option property at Gold Mountain. The objective of the WKM program is to further delineate the new at-surface gold outlined in 3,200 feet of road cuts and channel samples reported previously.

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:GMN / GOLD MOUNTAIN LIMITED on message board site Silicon Investor.

GMNI: Gemini Genomics plc GMNI: Gemini Genomics plc GMNI: Gemini Genomics plc